Clinical Trials Browser

Phase 2 × belzutifan × 90 days × Clear all

NCT04924075 2026-04-13

MK-6482-015

Phase 2 Recruiting

322 enrolled 3 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT06428396 2026-03-24

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms